SCHEMBL23218542

SCHEMBL23218542

CCc1oc2ccc(-c3cccc(CN)c3F)cc2c1COc1cc(OC)ccc1CC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.43
ANO1 Q5XXA6 4/20 0.40
SLC22A12 Q96S37 2/20 0.37
CFD P00746 3/20 0.37
MTNR1A P48039 4/20 0.36
MTNR1B P49286 3/20 0.36
PLG P00747 1/20 0.35
PLAU P00749 1/20 0.35
F11 P03951 1/20 0.35
KLKB1 P03952 1/20 0.35
F7 P08709 1/20 0.35
TPSB2 P20231 1/20 0.35
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
KDM4E B2RXH2 1/20 0.35
LCK P06239 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP12 P39900 1/20 0.35
PTGER1 P34995 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591501 1.00 CD274 (0.43) CD274ANO1SLC22A12CFDMTNR1A
SCHEMBL23218122 0.94 CD274 (0.42) CD274ANO1CFDMTNR1AMTNR1B
SCHEMBL29591469 0.94 CD274 (0.42) CD274ANO1CFDMTNR1AMTNR1B
SCHEMBL29852499 0.92 ANO1 (0.36) CD274ANO1SLC22A12CFDMTNR1A
SCHEMBL23218525 0.92 ANO1 (0.36) CD274ANO1SLC22A12CFDMTNR1A
SCHEMBL23218362 0.91 CD274 (0.46) CD274ANO1CFDPLGPLAU
SCHEMBL29591246 0.91 CD274 (0.46) CD274ANO1CFDPLGPLAU
SCHEMBL23218149 0.86 CFD (0.49) ANO1SLC22A12CFDMTNR1AMTNR1B
SCHEMBL29592827 0.86 CFD (0.49) ANO1SLC22A12CFDMTNR1AMTNR1B
SCHEMBL23218832 0.86 ANO1 (0.36) CD274ANO1CFDMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CD274 2774/4885ANO1 2994/4885SLC22A12 1513/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CD274 4001/4885ANO1 3834/4885SLC22A12 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.